Phase 2 SLE data shows deucravacitinib reduces CXCL10 by 42% at week 12 (88) and the IFN-5 (MX1, HERC5, IFIT1, RSAD2, EIF2AK2) gene signature score by up to 70% at Week 4 (89). Here, HERC5 is linked to systemic lupus erythematosus.